Logo
x

Search

Subscribe Now

Brukinsa

Top 20 Oncology Companies of 2024

Top 20 Oncology Companies of 2024

  • August 29, 2024
Insights+: EMA Marketing Authorization of New Drugs in October 2023

Insights+: EMA Marketing Authorization of New Drugs in October 2023

  • November 23, 2023
Insights+: The US FDA New Drug Approvals in November 2019

Insights+: The US FDA New Drug Approvals in November 2019

  • December 13, 2019
Insights+: EMA Marketing Authorization of New Drugs in October 2023

    Insights+: EMA Marketing Authorization of New Drugs in October 2023

    • November 23, 2023
    BeiGene’s Brukinsa with Obinutuzumab Receives the EC’s Approval for the Treatment of Follicular Lymphoma

      BeiGene’s Brukinsa with Obinutuzumab Receives the EC’s Approval for the Treatment of Follicular Lymphoma

      • November 20, 2023
      BeiGene’s Brukinsa (zanubrutinib) Receives the NICE Recommendation for Adult Patients with Chronic Lymphocytic Leukemia

        BeiGene’s Brukinsa (zanubrutinib) Receives the NICE Recommendation for Adult Patients with Chronic Lymphocytic Leukemia

        • October 20, 2023
        BeiGene’s Brukinsa Receive Positive Opinion from EU’s CHMP for the treatment of Follicular Lymphoma

          BeiGene’s Brukinsa Receive Positive Opinion from EU’s CHMP for the treatment of Follicular Lymphoma

          • October 13, 2023
          BeiGene Reports the US FDA Acceptance of sNDA for Brukinsa + Obinutuzumab for Adult Patients with R/R Follicular Lymphoma

            BeiGene Reports the US FDA Acceptance of sNDA for Brukinsa + Obinutuzumab for Adult Patients with R/R Follicular Lymphoma

            • July 12, 2023
            BeiGene’s Brukinsa (zanubrutinib) Receives the US FDA’s Approval for Chronic Lymphocytic Leukemia

              BeiGene’s Brukinsa (zanubrutinib) Receives the US FDA’s Approval for Chronic Lymphocytic Leukemia

              • January 20, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.